Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B ...

Inotuzumab ozogamicin, a CD22-directed ADC, has been assessed both as monotherapy and in combination with rituximab and rituximab-containing immunochemotherapy regimens in relapsed/refractory B ...